lunedì, 30 novembre 2020
15 Marzo 2018

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

March 13, 2018 – The FDA has granted a priority review to pembrolizumab for the treatment of advanced cervical cancer with disease progression on or after chemotherapy. The agency has set a PDUFA date of June 28, 2018. Merck, the developer of pembrolizumab, reported in a press release that this is the first time the FDA has given a priority review to an anti–PD-1 therapy in this disease. “Advanced cervical cancer is an illness with a poor prognosis and a high unmet … (leggi tutto)